3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Rectal Neoplasms
1
Pancreatic Cancer Resectable
1
Ovarian Carcinosarcoma
1
Neoplasms
1
Liver Neoplasms
1
Immune-related Adverse Event
1
Esophageal Neoplasms
1
Early Hormone Receptor-positive Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Solid Tumor
1
Interventions
Fulvestrant
58
Trastuzumab
49
Capecitabine
47
Letrozole
45
pembrolizumab
41
Carboplatin
41
Paclitaxel
39
Cyclophosphamide
38
ribociclib
37
pertuzumab
36
abemaciclib
36
Blood Specimen Collection
31
trastuzumab deruxtecan
27
Specimen Handling
27
Docetaxel
27
Surveys and Questionnaires
26
Anastrozole
25
exemestane
24
Tamoxifen
24
palbociclib
21
130-nm albumin-bound paclitaxel
21
Magnetic Resonance Spectroscopy
19
sacituzumab govitecan
18
eribulin
18
Radiotherapy
18
Gemcitabine
18
Biopsy
18
olaparib
17
Injections
17
Epirubicin
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Breast Neoplasms
×
Antineoplastic Agents
×
Clear all
NCT03591276
2020-10-23
KEYDOX
Shaare Zedek Medical Center
Phase 1/2
Recruiting
15 enrolled